Aneel Paulus

12PUBLICATIONS
78CO-AUTHORS
Haematological tumoursMolecular targetsImmunogenetics (incl. genetic immunology)Biomolecular modelling and designCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 07, 2026
A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.

|Apr 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi, Zi Chen, Bo Huang

|Jan 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.

Sikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta

|Dec 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.

Patrizia Mondello, Jonas Paludo, Joseph P Novak

|Sep 01, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

|Aug 17, 2022
CD38 as a multifaceted immunotherapeutic target in CLL.

Aneel Paulus, Fabio Malavasi, Asher Chanan-Khan

Pageof 2

Frequent Collaborators

7 joint publications

Sikander Ailawadhi

3 joint publications

Asher Chanan-Khan

3 joint publications

Jithma P Abeykoon

3 joint publications

Morie A Gertz